Treatment of hypophosphatemic rickets with phosphate and active vitamin D in Japan: A questionnaire-based survey

Clinical Pediatric Endocrinology

Volumn 22, Issue 1, 2012, Pages 9-14

  Fujiwara, Makoto ^a   Namba, Noriyuki ^a   Ozono, Keiichi ^a   Arisaka, Osamu ^b   Yokoya, Susumuy ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Active vitamin D; Hypophosphatemia; Phosphate; Phosphaturia; Rickets

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; GROWTH HORMONE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; VITAMIN D;

AGE DISTRIBUTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM URINE LEVEL; CHILD; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG MONITORING; ENDOCRINOLOGIST; HEALTH SURVEY; HUMAN; HYPOPHOSPHATEMIA; INFANT; JAPAN; MAJOR CLINICAL STUDY; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; QUESTIONNAIRE; SCHOOL CHILD; X LINKED HYPOPHOSPHATEMIC RICKETS;

EID: 84873539710     PISSN: 09185739     EISSN: 13477358     Source Type: Journal    
DOI: 10.1297/cpe.22.9     Document Type: Article

References (28)

1. Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010;6:657-65. [Medline] [CrossRef]
2. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012;30:1-9. [Medline] [CrossRef]
3. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8. [Medline] [CrossRef]
4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/ osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60. [Medline] [CrossRef]
5. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60:2079-86. [Medline] [CrossRef]
6. Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010;25:591-601. [Medline] [CrossRef]
7. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fbroblast growth factor 23. Mol Cell Endocrinol 2011;347:17-24. [Medline] [CrossRef]
8. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004;35:1192-9. [Medline] [CrossRef]
9. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifes a role for osteocytes in mineral metabolism. Nat Genet 2006;38:1310-5. [Medline] [CrossRef]
10. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010;86:273-8. [Medline] [CrossRef]
11. Lorenz-Depiereux B, Schnabel D, Tiosano D, Häusler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcifcation of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010;86:267-72. [Medline] [CrossRef]
12. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003;34:379-81. [Medline] [CrossRef]
13. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, et al. Bone proteins PHEX and DMP1 regulate fbroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011;25:2551-62. [Medline] [CrossRef]
14. Koshida R, Yamaguchi H, Yamasaki K, Tsuchimochi W, Yonekawa T, Nakazato M. A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets. J Bone Miner Metab 2010;28:585-90. [Medline] [CrossRef]
15. Saito T, Nishii Y, Yasuda T, Ito N, Suzuki H, Igarashi T, et al. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. Eur J Endocrinol 2009;161:647-51. [Medline] [CrossRef]
16. Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, et al. Growth-related renal type II Na/Pi cotransporter. J Biol Chem 2002;277:19665-72. [Medline] [CrossRef]
17. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, et al. Hereditary Hypophosphatemic Rickets with Hypercalciuria is Caused by Mutations in the Sodium-Phosphate Cotransporter Gene SLC34A3. Am J Hum Genet 2006;78:193-201. [Medline] [CrossRef]
18. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, et al. SLC34A3 Mutations in Patients with Hereditary Hypophosphatemic Rickets with Hypercalciuria Predict a Key Role for the Sodium-Phosphate Cotransporter NaPi-IIc in Maintaining Phosphate Homeostasis. Am J Hum Genet 2006;78:179-92. [Medline] [CrossRef]
19. Francis F, Hennig S, Korn B, Reinhardt R, Jong PD, Poustka A, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130-6. [Medline] [CrossRef]
20. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381-8. [Medline] [CrossRef]
21. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5. [Medline] [CrossRef]
22. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63. [Medline] [CrossRef]
23. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocrine-Related Cancer 2011;18:R53-77. [Medline] [CrossRef]
24. Kienitz T, Ventz M, Kaminsky E, Quinkler M. Novel PHEX nonsense mutation in a patient with X-linked hypophosphatemic rickets and review of current therapeutic regimens. Exp Clin Endocrinol Diabetes 2011;119:431-5. [Medline] [CrossRef]
25. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fbroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010;95:1846-50. [Medline] [CrossRef]
26. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 2010;95:E352-7. [Medline] [CrossRef]
27. Quinlan C, Guegan K, Offah A, Neill RO, Hiorns MP, Ellard S, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 2012;27:581-8. [Medline] [CrossRef]
28. Roth KS, Ward RJ, Chan JC, Sarafoglou K. Disorders of Calcium, Phosphate, and Bone Metabolism. In: Sarafoglou K, Hoffmann GF, Roth KS, editors. Pediatric Endocrinology and Inborn Errors of Metabolism. New York: McGraw Hill;2009.p.619-64.